Name of opportunity: 👀
Blueprint Medicines Corp
Strong growth predictions 📈
Blueprint Medicines has risen 18.22% in the past day, and is up by 13.17% in the past week. This stock is categorised as a growth stock, meaning it reinvests its profits to further the business’ growth. Blueprint Medicines has a high price to book ratio of 17.54.
Currently, Blueprint Medicines is performing well financially, with high gross margin, cash flow, and revenue. Analysts are recommending this stock as a ‘buy’ - could this be your next investment opportunity?
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of Blueprint Medicines Corp might increase from $103.36 to $119.94 in the next 12 months. If you invested $1000, you might profit $160.42.
One reason why Blueprint Medicines is rising in price might be because of the company’s predicted growth throughout 2025. As Blueprints Medicines’ life-changing drug, AYVAKIT, performed exceptionally well, the company had a 126.5% boost in revenue.
AYVAKIT is a medicine that is used to treat cancer (gastrointestinal stromal tumors) and mastocytosis in adults. The drug works by helping to slow down the growth of mast cells. This drug has meant Blueprint Medicines has made a name for itself in the world of pharmaceuticals, and the company plans to keep progressing. The company has several planned proof-of-concept trials for new drugs that should be taking place this coming year, looking at treatments for various allergic conditions including asthma and the rare condition mast cell activation syndrome (MCAS).
Global pharmaceutical company 💊
Blueprint Medicines Corp is a global precision therapy company that is headquartered in Massachusetts, United States. The company developed AYVAKIT, a drug to treat some types of cancer and mastocytosis.
Which neme?: 🔍
‘Top Gainers Today’, ‘Stocks On The Move’
Download Nemo Money to check out Blueprint Medicines, Corp. New users can grab our registration bonus up to a maximum of $50 on first deposit. Terms and conditions apply.
